RVPH Stock Analysis: Buy, Sell, or Hold?
RVPH - Reviva Pharmaceuticals Holdings, Inc. Common Stock
$0.35
-0.44 (-55.73%)
▼
5d:
-60.0%
30d:
-58.89%
90d:
+33.57%
WAIT
LOW Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 21, 2026
2d
Smart Money Accumulation
RVPH is down 60.0% this week, but smart money is accumulating calls. Top strike: $0.5 2026-07-17 with 11,487 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When RVPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called RVPH this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RVPH is down 60.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RVPH is down 60.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RVPH is currently trading at $0.35, which is considered oversold relative to its 30-day fair value range of $0.73 to $0.94.
Technical Outlook: Technically, RVPH is in a strong downtrend. Immediate support is located at $0.26, while resistance sits at $0.91. Short-term momentum is weak, with the stock down 55.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $58.20 (+16429.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RVPH is in a strong downtrend. Immediate support is located at $0.26, while resistance sits at $0.91. Short-term momentum is weak, with the stock down 55.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $58.20 (+16429.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.73 -
$0.94
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-55.7%)
- BULLISH: Trading 16429.4% below Wall St target ($58.20)
- WARNING: Recommendation downgraded due to -60.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.73 -
$0.94
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.26
Resistance Level
$0.91
Current Trend
Strong Downtrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.37
Wall Street Target
$58.20
(+16429.4%)
Share & Embed Analysis
Last updated: May 18, 2026 9:23 AM ET
Data refreshes hourly during market hours. Next update: 10:23 AM
Data refreshes hourly during market hours. Next update: 10:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RVPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 55 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$293 | 60 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 42 HOLD |
